Real-World Studies
Survival and Chemotherapy Benefit Across Intermediate ER Subgroups in HER2-Negative Breast Cancer
Yang et alThe Lancet Regional Health Europe
In HER2-negative breast cancer, clinical outcomes and tumor biology have traditionally been categorized around binary estrogen receptor (ER) thresholds or low (1–9%) versus high (≥60%) expression, leaving tumors expressing 10% to 59% ER poorly characterized. A nationwide population-based cohort study evaluated 75,211 women diagnosed with HER2-negative breast cancer in Sweden between 2007 and 2023 to evaluate real-world characteristics, treatment responses, and overall survival across the entire ER expression spectrum.
Patients were stratified into five distinct ER expression categories: ERzero (0%), ERlow (1–9%), ERmild (10–29%), ERmod (30–59%), and ERhigh (60–100%). Multivariable Cox proportional hazards modeling revealed that relative to ERhigh disease, mortality risks were significantly elevated for both ERmild (adjusted hazard ratio [aHR] = 1.59, 95% CI: 1.31–1.93, adjusted P < 0.001) and ERmod (aHR = 1.31, 95% CI: 1.17–1.47, adjusted P < 0.001) cohorts. Notably, ERmild cases displayed molecular features and survival curves that mirrored those observed in ERlow and ERzero disease.
Evaluating systemic therapy patterns demonstrated a pronounced survival advantage with combined chemoendocrine therapy over endocrine monotherapy in intermediate ER groups. The combination of chemotherapy and endocrine therapy was associated with a significant reduction in mortality compared to endocrine therapy alone in ERmild tumors (aHR = 0.46, 95% CI: 0.23–0.94, adjusted P = 0.033) and in ERmod tumors (aHR = 0.60, 95% CI: 0.42–0.85, adjusted P = 0.0046). These findings underscore the clinical necessity of reporting ER expression as an exact numerical percentage rather than broad positive/negative classifications to optimize risk stratification and adjuvant systemic therapy selection.
Key Takeaways
- Compared to ERhigh (60–100%) disease, overall survival was significantly worse in patients with ERmild (10–29%; aHR = 1.59, 95% CI: 1.31–1.93, P < 0.001) and ERmod (30–59%; aHR = 1.31, 95% CI: 1.17–1.47, P < 0.001) HER2-negative tumors.
- Combining chemotherapy with endocrine therapy significantly reduced the risk of death compared to endocrine therapy alone in both the ERmild (aHR = 0.46, 95% CI: 0.23–0.94, P = 0.033) and ERmod (aHR = 0.60, 95% CI: 0.42–0.85, P = 0.0046) cohorts.
- Patients with ERmild (10–29%) tumors demonstrated molecular characteristics and overall survival profiles closely resembling those of ERlow (1–9%) and ERzero subgroups.
Read the original sourceThe Lancet Regional Health Europe
